Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

Author： Rizzo Manfredi   Corrado Egle   Patti Angelo Maria   Rini Giovam Battista   Mikhailidis Dimitri P  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.4, 2011-03, pp. : 647-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

By  

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

By  

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3858-3868

Bentham Science Publishers

Access to resources Recommend Favorite

Is the Effect of Antihypertensive Drugs on Platelet Aggregability and Fibrinolysis Clinically Relevant?

By Fogari Roberto   Zoppi Annalisa  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 4, 2005-01 ,pp. : 211-223

Adis International

Access to resources Recommend Favorite

Chemokines and Relevant microRNAs in the Atherogenic Process

By  

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 7, 2018-03 ,pp. : 597-608

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment options for managing atherogenic dyslipidemia and fatty liver disease

By Rizzo Manfredi   Montalto Giuseppe   Al-Rasadi Khalid  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1065-1068

Informa Healthcare

Access to resources Recommend Favorite